Cardiac Systolic Function in Patients Receiving Hematopoetic Stem Cell Transplantation: Risk Factors for Posttransplantation Cardiac Toxicity

Transplantation Proceedings

Volumn 40, Issue 5, 2008, Pages 1586-1590

  Sucak, G T ^a   Ozkurt, Z N ^a   Aki, Z ^a   Yagci, M ^a   Cengel A ^a   Haznedar, R ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FERRITIN; FLUDARABINE; IDARUBICIN; MELPHALAN; MITOXANTRONE; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; FEMALE; FERRITIN BLOOD LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLE;

ADOLESCENT; ADULT; AGED; FEMALE; FERRITINS; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 45449116905     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.11.077     Document Type: Article

References (16)

1. Hertenstein B., Stefanic M., Schmeiser T., et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol 12 (1994) 998
2. Sakata-Yanagimoto M., Kanda Y., Nakagawa M., et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 33 (2004) 1043
3. Murdych T., and Weisdorf D.J. Serious cardiac complicarions during bone marrow transplantation at the University of Minnesota, 1977-1997. Bone Marrow Transplant 28 (2001) 283
4. Bearman S.I., Peterson F.B., Schor R.A., et al. Radionuclide ejection fractions in the evalution of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 5 (1990) 173
5. Cazin B., Gorin N.C., Laporte J.P., et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 57 (1986) 2061
6. Braverman A.C., Antin J.H., Plappert M.T., et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evalution of new dosing regimens. J Clin Oncol 9 (1991) 1215
7. Goldberg M.A., Antin J.H., Guinan E.C., et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68 (1986) 1114
8. Stewart G.R., and Fajardo L.F. Radiation-induced heart disease: an update. Prog Cardio Dis 17 (1984) 173
9. Fujimaki K., Maruta A., Yoshida M., et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 27 (2001) 307
10. Herait P., and Poutignat N. Early assessment of a new anticancer drug analogue-are the historical comparisons obsolete?. The French experience with pirarubicin. Eur J Cancer 28A (1992) 1670
11. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 (2007) 4586
12. Coghlan J.G., Handler C.E., Kottaridis P.D., et al. Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 20 (2007) 247
13. Lehmann S., Isberg B., Ljungman P., et al. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant 26 (2000) 187
14. Davis J.M., Rowley S.D., Braine H.G., et al. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 75 (1990) 781
15. Zenhausern R., Tobler A., Leoncini L., et al. Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol 79 (2000) 523
16. Rabkin J.M., Corless C.L., Rosen H.R., et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 183 (2002) 595